122 related articles for article (PubMed ID: 12932898)
1. How a single inversion of configuration leads to a reversal of the binding mode: proposal of a novel arrangement of CCK2 ligands in their receptor, and contribution to the development of peptidomimetic or non-peptide CCK2 ligands.
Bellier B; Garbay C
Eur J Med Chem; 2003; 38(7-8):671-86. PubMed ID: 12932898
[TBL] [Abstract][Full Text] [Related]
2. New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454.
Bellier B; Crété D; Million ME; Beslot F; Bado A; Garbay C; Daugé V
Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):404-13. PubMed ID: 15480577
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand.
Kalindjian SB; McDonald IM
Curr Top Med Chem; 2007; 7(12):1195-204. PubMed ID: 17584141
[TBL] [Abstract][Full Text] [Related]
5. Conformationally readdressed CCK-B/delta-opioid peptide ligands.
Nikiforovich GV; Kolodziej SA; Nock B; Bernad N; Martinez J; Marshall GR
Biopolymers; 1995 Oct; 36(4):439-52. PubMed ID: 7578939
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties.
Bellier B; Dugave C; Etivant F; Genet R; Gigoux V; Garbay C
Bioorg Med Chem Lett; 2004 Jan; 14(2):369-72. PubMed ID: 14698161
[TBL] [Abstract][Full Text] [Related]
7. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.
Fourmy D; Escrieut C; Archer E; Galès C; Gigoux V; Maigret B; Moroder L; Silvente-Poirot S; Martinez J; Fehrentz JA; Pradayrol L
Pharmacol Toxicol; 2002 Dec; 91(6):313-20. PubMed ID: 12688374
[TBL] [Abstract][Full Text] [Related]
8. Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode.
Bellier B; Million ME; DaNascimento S; Meudal H; Kellou S; Maigret B; Garbay C
J Med Chem; 2000 Oct; 43(20):3614-23. PubMed ID: 11020275
[TBL] [Abstract][Full Text] [Related]
9. Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
Low CM; Black JW; Broughton HB; Buck IM; Davies JM; Dunstone DJ; Hull RA; Kalindjian SB; McDonald IM; Pether MJ; Shankley NP; Steel KI
J Med Chem; 2000 Sep; 43(19):3505-17. PubMed ID: 11000005
[TBL] [Abstract][Full Text] [Related]
10. CCK1 and 2 receptors are expressed in immortalized rat brain neuroblasts: intracellular signals after cholecystokinin stimulation.
Langmesser S; Cerezo-Guisado MI; Lorenzo MJ; Garcia-Marin LJ; Bragado MJ
J Cell Biochem; 2007 Mar; 100(4):851-64. PubMed ID: 17226751
[TBL] [Abstract][Full Text] [Related]
11. The cholecystokinin receptor agonist, CCK-8, induces adiponectin production in rat white adipose tissue.
Plaza A; Merino B; Del Olmo N; Ruiz-Gayo M
Br J Pharmacol; 2019 Aug; 176(15):2678-2690. PubMed ID: 31012948
[TBL] [Abstract][Full Text] [Related]
12. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
14. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
Stone SR; Giragossian C; Mierke DF; Jackson GE
Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of CCKRs and SAR studies of peptidic analog ligands.
Noble F
Curr Top Med Chem; 2007; 7(12):1173-9. PubMed ID: 17584139
[TBL] [Abstract][Full Text] [Related]
16. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
Dong M; Miller LJ
Peptides; 2013 Aug; 46():143-9. PubMed ID: 23770253
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin antagonists: pharmacological and therapeutic potential.
Herranz R
Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
[TBL] [Abstract][Full Text] [Related]
18. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
Foucaud M; Archer-Lahlou E; Marco E; Tikhonova IG; Maigret B; Escrieut C; Langer I; Fourmy D
Regul Pept; 2008 Jan; 145(1-3):17-23. PubMed ID: 17961734
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
[TBL] [Abstract][Full Text] [Related]
20. Sequence variation outside the "active" region of dog and rabbit cholecystokinin-58 results in bioactivity differences.
Reeve JR; Liddle RA; Shively JE; Lee TD; Keire DA; Chew P; Vigna SR
Pancreas; 2006 Apr; 32(3):306-13. PubMed ID: 16628087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
